American Assets Investment Management LLC Has $2.43 Million Holdings in Pfizer Inc. (NYSE:PFE)

Key Points

• American Assets Investment Management LLC reduced its stake in Pfizer by 56.4% in the first quarter, owning 96,000 shares valued at approximately $2.43 million after selling 124,000 shares.
• Pfizer's stock opened at $23.56 and has a market cap of $133.95 billion with a P/E ratio of 17.07.
• The company announced a quarterly dividend of $0.43 per share, reflecting a 7.3% dividend yield and a payout ratio of 124.64%.

American Assets Investment Management LLC lessened its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 56.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 96,000 shares of the biopharmaceutical company's stock after selling 124,000 shares during the quarter. American Assets Investment Management LLC's holdings in Pfizer were worth $2,433,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer in the 4th quarter valued at approximately $27,000. Gould Capital LLC boosted its holdings in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 493 shares during the last quarter. Bayforest Capital Ltd acquired a new stake in shares of Pfizer in the 1st quarter valued at approximately $28,000. North Capital Inc. bought a new stake in Pfizer in the 1st quarter valued at $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in Pfizer in the 4th quarter valued at $30,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Performance

NYSE:PFE opened at $23.56 on Tuesday. The business's 50-day moving average price is $24.37 and its two-hundred day moving average price is $24.53. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The stock has a market cap of $133.95 billion, a P/E ratio of 17.07, a PEG ratio of 0.85 and a beta of 0.52. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 7.3%. Pfizer's dividend payout ratio is 124.64%.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Bank of America increased their price target on Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Leerink Partners dropped their price target on Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a research note on Wednesday, April 30th. Redburn Atlantic dropped their price target on Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 30th. UBS Group increased their price target on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Finally, BMO Capital Markets dropped their price target on Pfizer from $36.00 to $30.00 in a research note on Thursday, April 17th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, six have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $28.28.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.